

CONSORT Statement 1996 Checklist

Consolidation of Standards for Reporting Trials—CONSORT^{3,4}

Heading	Subheading	Descriptor	Was It Reported?	On What Page No.?
Title		Identify the study as a randomized trial. ⁷		
Abstract		Use a structured format. ^{5,9}		
Introduction		State prospectively defined hypothesis, clinical objectives, and planned subgroup or covariate analyses. ¹⁰		
Methods	Protocol	Describe		
		Planned study population, together with inclusion/exclusion criteria.		
		Planned interventions and their timing.		
		Primary and secondary outcome measure(s) and the minimum important difference(s), and indicate how the target sample size was projected. ^{2,11}		
Assignment	Assignment	Rationale and methods for statistical analyses, detailing main comparative analyses and whether they were completed on an intention-to-treat basis. ^{12,13}		
		Prospectively defined stopping rules (if warranted). ¹⁴		
		Describe		
		Unit of randomization (eg, individual, cluster, geographic). ¹⁵		
Masking (Blinding)	Masking (Blinding)	Method used to generate the allocation schedule. ¹⁶		
		Method of allocation concealment and timing of assignment. ¹⁷		
		Method to separate the generator from the executor of assignment. ^{17,18}		
		Describe mechanism (eg, capsules, tablets); similarity of treatment characteristics (eg, appearance, taste); allocation schedule control (location of code during trial and when broken); and evidence for successful blinding among participants, person doing intervention, outcome assessors, and data analysts. ^{19,20}		
Results	Participant Flow and Follow-up	Provide a trial profile (Figure) summarizing participant flow, numbers and timing of randomization assignment, interventions, and measurements for each randomized group. ^{3,21}		
	Analysis	State estimated effect of intervention on primary and secondary outcome measures, including a point estimate and measure of precision (confidence interval). ^{22,23} State results in absolute numbers when feasible (eg, 10/20, not 50%). Present summary data and appropriate descriptive and inferential statistics in sufficient detail to permit alternative analyses and replication. ²⁴ Describe prognostic variables by treatment group and any attempt to adjust for them. ²⁵ Describe protocol deviations from the study as planned, together with the reasons.		
Comment		State specific interpretation of study findings, including sources of bias and imprecision (internal validity) and discussion of external validity, including appropriate quantitative measures when possible.		
		State general interpretation of the data in light of the totality of the available evidence.		

Improving the Quality of Reporting of Randomized Controlled Trials

The CONSORT Statement

Colin Begg, PhD; Mildred Cho, PhD; Susan Eastwood, ELS(D); Richard Horton, MB; David Moher, MSc; Ingram Olkin, PhD; Roy Pitkin, MD; Drummond Rennie, MD; Kenneth F. Schulz, PhD; David Simel, MD; Donna F. Stroup, PhD